Indiabulls Ltd. (IBULLSLTD) — Tipsheet https://tipsheet.markets/company/ibullsltd/ Every Tipsheet Editorial note covering Indiabulls Ltd. (IBULLSLTD), newest first. Grounded in BSE/NSE primary-source filings. en-in Tue, 28 Jul 2026 14:38:34 GMT Indiabulls to raise ₹1,000 cr from promoters and funds via convertible warrants https://tipsheet.markets/ibullsltd-indiabulls-to-raise-1-000-cr-from-promoters-and-funds-via-convertible-warrants-105182/ https://tipsheet.markets/ibullsltd-indiabulls-to-raise-1-000-cr-from-promoters-and-funds-via-convertible-warrants-105182/ Wed, 03 Jun 2026 17:31:23 GMT The ₹19.40-a-share warrant issue, convertible in 18 months, will dilute shareholders by 19.3% of current market cap. Promoters Hermes and Phanes are in. The ₹19.40-a-share warrant issue, convertible in 18 months, will dilute shareholders by 19.3% of current market cap. Promoters Hermes and Phanes are in.

What’s new

  • Board approves ₹1,000 cr raise via 51.55 crore convertible warrants priced at ₹19.40 each.
  • Promoters Hermes Ltd and Phanes Ltd, plus funds EBISU and Nyaasa, are taking the warrants.
  • Conversion window is 18 months; shareholder approval vote is set for July 2.

Why it matters

A ₹1,000 cr equity raise is 19.3% of Indiabulls' current market capitalization. That level of dilution, locked in by promoters and external funds alike, is a clear balance-sheet reset. The question is what the company does with the cash.

What we’re watching

  • How Indiabulls deploys ₹1,000 cr — debt reduction, project launches, or something else.
  • Whether the ₹19.40 issue price holds as a support level post-conversion.
  • Any promoter selling after the 18-month lock-in expires.

The full read

Indiabulls is raising ₹1,000.07 crore through convertible warrants priced at ₹19.40 each. The subscribers include promoters Hermes and Phanes, alongside funds EBISU and Nyaasa. Once converted within 18 months, the new equity will amount to 19.3% of the company's current market cap. For a mid-cap, that's a large hit to the existing share register. The board is betting the capital infusion outweighs the dilution. What matters now is the allocation: whether the ₹1,000 cr goes to shore up the balance sheet after its recent merger or to fund new projects. The July 2 shareholder vote is the first checkpoint.

Primary source: BSE · NSE

]]> Credit Tipsheet Editorial